Flash note: PacificGMP time
Abzena’s £4.98m cash acquisition of PacificGMP is a logical and positive move as the group seeks to enhance its downstream biomanufacturing capabilities and build out its US operations. With PacificGMP generating FY15 revenues of $3m (£1.9m), the deal is priced at just 2.6x sales and is expected to be immediately accretive to earnings (before amortisation of acquired intangible assets). We place our financial forecasts and valuation under review to assess the full impact of the deal, but see PacificGMP adding significantly to Abzena’s value proposition for its partners.Abzena is providing a range of complementary services and technologies for the selection, development and manufacture of biopharmaceuticals.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.